Kenvue Inc. (NYSE:KVUE) Stock Holdings Lifted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 28.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 228,598 shares of the company’s stock after buying an additional 50,073 shares during the period. Nisa Investment Advisors LLC’s holdings in Kenvue were worth $5,287,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Janney Montgomery Scott LLC lifted its holdings in shares of Kenvue by 56.2% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,840,875 shares of the company’s stock worth $39,505,000 after purchasing an additional 662,666 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Kenvue in the first quarter valued at $1,050,000. Norden Group LLC acquired a new position in shares of Kenvue during the first quarter valued at $1,792,000. Lorne Steinberg Wealth Management Inc. grew its position in shares of Kenvue by 59.0% during the second quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company’s stock worth $2,812,000 after acquiring an additional 57,375 shares during the last quarter. Finally, Kennon Green & Company LLC increased its holdings in shares of Kenvue by 140.7% in the 2nd quarter. Kennon Green & Company LLC now owns 159,106 shares of the company’s stock worth $2,893,000 after acquiring an additional 93,008 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.2 %

NYSE KVUE opened at $22.93 on Friday. The company has a market capitalization of $43.91 billion, a P/E ratio of 39.53, a PEG ratio of 3.00 and a beta of 1.40. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The company’s 50 day simple moving average is $22.51 and its 200 day simple moving average is $20.38.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 EPS. Equities research analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.58%. Kenvue’s dividend payout ratio (DPR) is 141.38%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Citigroup decreased their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a research note on Tuesday, September 24th. Piper Sandler increased their price target on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. UBS Group lifted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.